Period of time： 1999年4期
Publisher： Elsevier
Founded in： 1995
Total resources： 4
ISSN： 1380-2933
Subject： R3 Basic Medical
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Immunotechnology,volume 3,issue 4
Menu
The TH1/TH2 paradigm in allergy
Immunotechnology,volume 3,issue 4 , Vol. 3, Iss. 4, 1998-01 , pp.
Access to resources
Recommend
Determination of T-lymphocyte adhesion to endothelial cells using a novel luminescence marker
By Termeer C.C., Weiss J.M., Dittmar H., Vanscheidt W., Schopf E., Simon J.C. in (1998)
Immunotechnology,volume 3,issue 4 , Vol. 3, Iss. 4, 1998-01 , pp.Three-dimensional structure of a human Fab with high affinity for tetanus toxoid
By Faber C., Shan L., Fan Z.-c., Guddat L.W., Furebring C., Ohlin M., Borrebaeck C.A.K., Edmundson A.B. in (1998)
Immunotechnology,volume 3,issue 4 , Vol. 3, Iss. 4, 1998-01 , pp.A definitive set of oligonucleotide primers for amplifying human V regions
By Sblattero D., Bradbury A. in (1998)
Immunotechnology,volume 3,issue 4 , Vol. 3, Iss. 4, 1998-01 , pp.By Watzka H., Pfizenmaier K., Moosmayer D. in (1998)
Immunotechnology,volume 3,issue 4 , Vol. 3, Iss. 4, 1998-01 , pp.Pathfinder selection: in situ isolation of novel antibodies
By Osbourn J.K., Derbyshire E.J., Vaughan T.J., Field A.W., Johnson K.S. in (1998)
Immunotechnology,volume 3,issue 4 , Vol. 3, Iss. 4, 1998-01 , pp.Therapeutic Antibody Technology 97
By Larrick J.W., Gavilondo J. in (1998)
Immunotechnology,volume 3,issue 4 , Vol. 3, Iss. 4, 1998-01 , pp.Progress in programming antibody fragments to crystallize
By Edmundson A.B., Borrebaeck C.A.K. in (1998)
Immunotechnology,volume 3,issue 4 , Vol. 3, Iss. 4, 1998-01 , pp.